BioForce enters cost-saving Dx agreement with Aspera
This article was originally published in Clinica
Executive Summary
Nanotechnology company BioForce Nanosciences has licensed its scientific applications to Aspera, a firm focused on developing miniaturised biomolecular detection systems. Aspera, which was started up by former BioForce employees to develop technologies licensed from the latter, has gained non-exclusive rights to products such as the ViriChip, Chip-on-a-Tip and CellWell diagnostic and detection systems.